- Conditions
- Active Polyarticular Juvenile Idiopathic Arthritis
- Interventions
- Abatacept
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Hartford, Connecticut + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–17
of 17
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- CP-690,550 (tofacitinib), placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 55
- States / cities
- Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 24 more
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- CNTO 148 (Golimumab), Placebo, Methotrexate
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Augusta, Georgia + 4 more
- Conditions
- Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
- Interventions
- Certolizumab Pegol (CZP)
- Drug
- Lead sponsor
- UCB BIOSCIENCES GmbH
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- Polyarticular Juvenile Rheumatoid Arthritis, Arthritis, Juvenile Idiopathic
- Interventions
- Not listed
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Palo Alto, California • San Diego, California + 41 more
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Chicago, Illinois • Hackensack, New Jersey + 6 more
- Conditions
- Juvenile Idiopathic Arthritis (JIA)
- Interventions
- allogeneic Hope Biosciences adipose-derived mesenchymal stem cells, Normal Saline Solution 0.9%
- Biological · Other
- Lead sponsor
- Hope Biosciences Research Foundation
- Industry
- Eligibility
- 2 Years to 16 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Sugar Land, Texas
- Conditions
- Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
- Interventions
- 40 mg MSB11022
- Drug
- Lead sponsor
- Fresenius Kabi SwissBioSim GmbH
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 216 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • Salt Lake City, Utah
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Tocilizumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 10
- States / cities
- Hartford, Connecticut • Washington D.C., District of Columbia • Delray Beach, Florida + 7 more
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Sarilumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Arthritis, Juvenile
- Interventions
- Golimumab, Methotrexate
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 14
- States / cities
- San Diego, California • Chicago, Illinois • Boston, Massachusetts + 11 more
- Conditions
- Arthritis, Juvenile Idiopathic
- Interventions
- Double-Blind Adalimumab/Placebo + MTX, Double-Blind Adalimumab/Placebo, OLE BSA Adalimumab +/- MTX, OLE FD Adalimumab +/- MTX
- Biological · Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 10
- States / cities
- Hartford, Connecticut • Chicago, Illinois • Hackensack, New Jersey + 6 more
- Conditions
- Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
- Interventions
- TNFi (Tumor Necrosis Factor inhibitor) medication, Abatacept, Tocilizumab, Tofacitinib
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 4
- States / cities
- San Francisco, California • Gainesville, Florida • Hackensack, New Jersey + 1 more
- Conditions
- Juvenile Idiopathic Arthritis, JIA
- Interventions
- adalimumab, Methotrexate
- Biological · Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 849 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2024
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 28 more
- Conditions
- Juvenile Rheumatoid Arthritis
- Interventions
- Abatacept, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 10
- States / cities
- Omaha, Nebraska • Livingston, New Jersey • New Hyde Park, New York + 7 more
- Conditions
- Juvenile Idiopathic Arthritis (JIA)
- Interventions
- Upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Louisville, Kentucky • Boston, Massachusetts + 5 more